Search

Search Constraints

You searched for: Author/Creator Campioni, Marco

Search Results

1. A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy. (3rd August 2019)

2. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. Issue 1 (2nd January 2020)

3. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. (1st November 2016)

4. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Issue 12 (2nd December 2017)

7. Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making. Issue 1 (January 2019)

8. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy. (4th May 2018)

9. Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review. Issue 7 (14th July 2020)